Upadacitinib is associated with clinical response and steroid‐free remission for children and adolescents with inflammatory bowel disease
Therapeutic options for children with IBD remain limited. In cases refractory to approved agents, our experience suggests that upadacitinib is effective with no new safety signals in a small subset of patients with IBD (ages 9-20 years) treated at a children's hospital.
Authors
- Jennifer Strople (ORCID: https://orcid.org/0000-0001-5357-9755)
- Kelsey Ryan (ORCID: https://orcid.org/0009-0002-1280-1326)
- Joseph Runde (ORCID: https://orcid.org/0000-0001-5556-0660)
- Jeffrey B. Brown (ORCID: https://orcid.org/0000-0002-0786-3189)
- Jonathan Lebowitz
- Joseph Hirst (ORCID: https://orcid.org/0009-0006-9598-2159)
- Wenya Chen (ORCID: https://orcid.org/0000-0002-3230-4514)
Institutions
- Northwestern University (US)
- Lurie Children's Hospital (US)
Publication Details
- Journal
- Journal of Pediatric Gastroenterology and Nutrition
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1002/jpn3.12408
- Citations
- 15
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 8.25